Page 216 - Drug Class Review
P. 216
Page 138 of 205
Drug Effectiveness Review Project
placebo 85.9 82 NR 14.4 20.5 Timing of assessments: Screening, baseline, and 4 week intervals throughout study No significant differences in PSMS change from baseline between DON and placebo No statistical or clinically significant differences in mean NPI-NH total scores observed between No statistically significant differences in mean MMSE change from baseline at endpoint Significantly greater improvement in CDR-SB total score and cognitive subscale for DON
Alzheimer classification: Mild-moderate
Groups similar at baseline: Yes
Health Outcome Measures:
donepezil 85.4 83 NR 14.4 21.0 Primary Outcome Measures: NPI-NH Secondary Outcome Measures: MMSE; CDR-SB; PSMS DON and placebo at any time points* Intermediate Outcome Measures: compared to placebo (P < 0.05)
• • • •
Final Report Update 1 Authors: Tariot et al. Year: 2001 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: Other germane population qualities: MMSE • NPI-NH • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
